Compare Crispr Therapeutics AG (CRSP) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Firy Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Firy Inc. trades at $12.07 (market cap $199.80M). The key difference: Crispr Therapeutics AG is far larger — about 24.4× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Firy Inc. for 13 Days on average.
| CRSP | FIRY | |
|---|---|---|
Market Cap | $4.88B | $199.80M |
Volume | 2,861,747 | 92,993 |
Sector | Health | Technology |
52-Week High | $74.92 | $13.10 |
52-Week Low | $44.34 | $2.28 |
Typical Hold Time | 77 Days | 13 Days |
Enterprise Value | $3.30B | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
FIRY trades at $12.02, up 1.43% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but missed EPS expectations with a net loss. Recent developments include a $719M legal victory and board appointment of Marc Lasry, though cash flow remains negative with -$86.41M in 2025.
Outlook is mixed: the legal win and restructuring offer potential upside, but persistent losses and cash burn pose significant risks. Analyst consensus is cautious with 60% hold ratings. The stock's valuation at P/S 1.6x appears reasonable, but profitability challenges and negative margins require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
